Challenges of scale in cell therapy manufacturing
This webinar is no longer available. Gain insights into how to scale your cell therapy manufacturing process through the use of a functionally closed, automated cell culture process.
This webinar is no longer available
Moving a promising cell therapy from the initial discovery phase through to clinical trials and therapeutic delivery poses a number of challenges. An evolving process not only must clear regulatory hurdles and scale to meet dose and lot size requirements but also must maintain economic value. In addition to discussing these challenges, Dr Beltzer (Terumo BCT, CO, USA) will present a number of case studies to describe how process development and economic goals were achieved in both industry and academic settings, including ReGenesys, UC Davis, and the Baylor College of Medicine. Particular attention will be directed toward the process changes often needed to meet these goals.
What will you learn?
- New approach to scaling cell-based therapy manufacturing processes
- Case studies on cost and labor savings achieved
- New approach to production of mesenchymal stem cells (MSCs)
- New approach to viral vector production
- New approach to dendritic cell maturation
Who may this interest?
- Clinicians, researchers, lab technologists and industry professionals
- Cell therapy manufacturing professionals
- Gene and immunotherapy manufacturing professionals
Jim Beltzer, PhD
Senior Cell Processing Specialist
Prior to joining the Cell Processing team at Terumo BCT, Dr Beltzer was the lead scientist for the research and development of Corning® Synthemax®, a synthetic growth surface for the culture of human embryonic stem cells at Corning Life Sciences. He was a co-founder of RETT Corporation and was a key player in the industrialization of several technology platforms, including phage display and yeast two-hybrid. He has more than 20 years of industrial research and development experience in a broad range of disciplines.